We visited eight pharmaceutical companies in Hyderabad recently. Since growth challenges and regulatory issues bedevil many large-caps, we believe mid-caps may well provide interesting opportunities to investors. We have segregated these companies into three broad categories: (1) Established formulations players, (2) Emerging formulations players and (3) CRAMS players.